A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
暂无分享,去创建一个
[1] S. Culine,et al. The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. , 2000, European journal of cancer.
[2] L. Zelek,et al. Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] L. Collette,et al. Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC / MRC Phase III Study , 2000 .
[4] C. Meisner,et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] E. Cvitkovic. Bleomycin in nonseminomatous germ-cell tumors: cure rate versus morbidity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R Sylvester,et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] L. Collette,et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R H Begent,et al. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Fosså,et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] D. Bajorin,et al. Bleomycin in germ cell tumor therapy: not all regimens are created equal. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Culine,et al. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors. , 1997, American journal of clinical oncology.
[12] P. Wilkinson,et al. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Bokemeyer,et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Culine,et al. Chemotherapy in adult germ cell tumors. , 1996, Critical reviews in oncology/hematology.
[15] L. Einhorn,et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Ravi. Growing teratoma syndrome. , 1995, Urologia internationalis.
[17] S. Kaye,et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Gerson,et al. Low Toxicity with Continuous Infusion of High‐Dose Bleomycin in Poor Prognostic Testicular Cancer , 1993, American journal of clinical oncology.
[19] V. Harvey,et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Geller,et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Wozniak,et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Goel,et al. The effect of corticosteroid administration on bleomycin lung toxicity , 1990, Cancer.
[23] L. Einhorn,et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] N. Geller,et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Théodore,et al. Prognostic factors in advanced nonseminomatous testicular cancer a multivariate logistic regression analysis , 1988, Cancer.
[26] J. Lazo,et al. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. , 1987, The Journal of pharmacology and experimental therapeutics.
[27] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[28] C. Logothetis,et al. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Venna,et al. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. , 1987, The American journal of medicine.
[30] C. Logothetis,et al. Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients. , 1986, The American journal of medicine.
[31] L. Einhorn,et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Logothetis,et al. Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N. Vogelzang. Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] N. Geller,et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. , 1983, Cancer research.
[35] C. Logothetis,et al. Sequential chemotherapy with cytoxan, adriamycin, and cis-platinum alternating with velban-bleomycin for stage III germinal cancer with poor prognosis , 1982 .
[36] L. Einhorn,et al. The role of maintenance therapy in disseminated testicular cancer. , 1981, The New England journal of medicine.
[37] R. Makuch,et al. Sample size requirements for evaluating a conservative therapy. , 1978, Cancer treatment reports.
[38] R. Golbey,et al. High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.
[39] D. Johnson,et al. Clinical trial of bleomycin (NSC-125066) in the treatment of metastatic renal carcinoma. , 1975, Cancer chemotherapy reports.